Milestone Pharmaceuticals Says US FDA Approves Cardamyst Spray for Supraventricular Tachycardia Episodes

MT Newswires Live12-15

Milestone Pharmaceuticals (MIST) said Friday that the US Food and Drug Administration has approved its Cardamyst nasal spray for the conversion of acute episodes of paroxysmal supraventricular tachycardia to sinus rhythm in adults.

This approval means 2 million Americans with paroxysmal supraventricular tachycardia can have access to the potentially self-administered treatment, the company said.

The drug will be available in pharmacies in Q1 2026.

The approval followed a clinical trial program involving 1,800 participants and 2,000 episodes of paroxysmal supraventricular tachycardia, which showed benefits for 73% of patients after 60 minutes, the company said.

Paroxysmal supraventricular tachycardia results in episodes of fast heart rates, the company said.

Shares of the company were down 18% in recent premarket activity.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment